Posts

Posted on

Costco Wholesale Corporation Reports Fourth Quarter and Fiscal Year 2026 Operating Results

ISSAQUAH, Wash., Sept. 24, 2026 (GLOBE NEWSWIRE) — Costco Wholesale Corporation (“Costco” or the “Company”) (Nasdaq: COST) today announced its operating results for the 16-week fourth quarter and the 52-week fiscal year ended August 30, 2026.

Net sales for the quarter increased 11.2 percent, to $93.9 billion, from $84.4 billion last year. Net sales for the fiscal year increased 10.1 percent, to $297.2 billion, from $269.9 billion last year.

Comparable sales for the fourth quarter and fiscal year were as follows:

  16 Weeks   16 Weeks   52 Weeks   52 Weeks
      Adjusted*       Adjusted*
U.S. 10.7%   7.2%   8.2%   6.6%
Canada 5.0%   4.6%   7.8%   6.7%
Other International 7.0%   6.2%   9.8%   6.5%
               
Total Company 9.4%   6.7%   8.4%   6.6%
               
Digitally-Enabled 19.5%   19.8%   20.9%   20.7%

*Excluding the impacts from changes in gasoline prices and foreign exchange.

Net income for the fourth quarter was $2.998 billion, $6.75 per diluted share, compared to $2.610 billion, $5.87 per diluted share, last year. This year’s fourth quarter was positively impacted by a non-recurring benefit of $0.15 per diluted share from IEEPA tariff refunds received in the quarter, less partial reinvestment of those refunds in increased member values. Net income for the fiscal year was $9.226 billion, $20.76 per diluted share, compared to $8.099 billion, $18.21 per diluted share, last year.

Costco currently operates 939 warehouses, including 647 in the United States and Puerto Rico, 115 in Canada, 43 in Mexico, 37 in Japan, 29 in the United Kingdom, 20 in Korea, 15 in Australia, 14 in Taiwan, seven in China, five in Spain, three in France, two in Sweden, and one each in Iceland, and New Zealand. Costco also operates e-commerce sites in the U.S., Canada, the U.K., Mexico, Korea, Taiwan, Japan, Australia, and China.

A conference call to discuss these results is scheduled for 2:00 p.m. (PT) today, September 24, 2026, and will be available via a webcast on investor.costco.com (click “Events & Presentations”).

Certain statements contained in this document constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For these purposes, forward-looking statements are statements that address activities, events, conditions or developments that the Company expects or anticipates may occur in the future. In some cases forward-looking statements can be identified because they contain words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or similar expressions and the negatives of those terms. Such forward-looking statements involve risks and uncertainties that may cause actual events, results or performance to differ materially from those indicated by such statements. These risks and uncertainties include, but are not limited to, domestic and international economic conditions, including exchange rates, inflation or deflation, the effects of competition and regulation, uncertainties in the financial markets, consumer and small business spending patterns and debt levels, breaches of security or privacy of member or business information, conditions affecting the acquisition, development, ownership or use of real estate, capital spending, actions of vendors, rising costs associated with employees (generally including health-care costs and wages), workforce interruptions, energy and certain commodities, geopolitical conditions (including tariffs and global conflicts), the ability to maintain effective internal control over financial reporting, regulatory and other impacts related to environmental and social matters, public-health related factors, and other risks identified from time to time in the Company’s public statements and reports filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company does not undertake to update these statements, except as required by law. Comparable sales and comparable sales excluding impacts from changes in gasoline prices and foreign exchange are intended as supplemental information and are not a substitute for net sales presented in accordance with U.S. GAAP.

CONTACTS: Costco Wholesale Corporation
  Josh Dahmen, 425/313-8254
  Andrew Yoon, 425/313-6305
  Bryan Starnes, 425/427-7403
   

COST-Earn

COSTCO WHOLESALE CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
(dollars in millions, except per share data) (unaudited)
       
  16 Weeks Ended   52 Weeks Ended
  August 30, 2026   August 31, 2025   August 30, 2026   August 31, 2025
REVENUE              
Net sales         $ 93,873     $ 84,432     $ 297,247     $ 269,912  
Membership fees           1,850       1,724       5,907       5,323  
Total revenue           95,723       86,156       303,154       275,235  
OPERATING EXPENSES              
Merchandise costs           83,531       75,037       264,279       239,886  
Selling, general and administrative           8,391       7,778       27,190       24,966  
Operating income           3,801       3,341       11,685       10,383  
OTHER INCOME (EXPENSE)              
Interest expense           (45 )     (46 )     (145 )     (154 )
Interest income and other, net           253       215       711       589  
INCOME BEFORE INCOME TAXES   4,009       3,510       12,251       10,818  
Provision for income taxes           1,011       900       3,025       2,719  
NET INCOME         $ 2,998     $ 2,610     $ 9,226     $ 8,099  
               
NET INCOME PER COMMON SHARE:              
Basic         $ 6.75     $ 5.88     $ 20.78     $ 18.24  
Diluted         $ 6.75     $ 5.87     $ 20.76     $ 18.21  
               
Shares used in calculation (000’s):              
Basic           443,975       444,007       443,953       443,985  
Diluted           444,364       444,706       444,427       444,803  
               



COSTCO WHOLESALE CORPORATION
CONSOLIDATED BALANCE SHEETS
(amounts in millions, except par value and share data) (unaudited)
       
Subject to Reclassification      
  August 30,

2026 		  August 31,

2025
ASSETS      
CURRENT ASSETS      
Cash and cash equivalents         $ 20,207     $ 14,161  
Short-term investments           1,094       1,123  
Receivables, net           3,959       3,203  
Merchandise inventories           19,324       18,116  
Other current assets           1,998       1,777  
Total current assets           46,582       38,380  
OTHER ASSETS      
Property and equipment, net           35,633       31,909  
Operating lease right-of-use assets           2,697       2,725  
Other long-term assets           4,133       4,085  
TOTAL ASSETS         $ 89,045     $ 77,099  
LIABILITIES AND EQUITY      
CURRENT LIABILITIES      
Accounts payable         $ 22,591     $ 19,783  
Accrued salaries and benefits           5,641       5,205  
Accrued member rewards           3,037       2,677  
Deferred membership fees           3,006       2,854  
Current portion of long-term debt           2,248       75  
Other current liabilities           7,429       6,514  
Total current liabilities           43,952       37,108  
OTHER LIABILITIES      
Long-term debt, excluding current portion           3,914       5,713  
Long-term operating lease liabilities           2,414       2,460  
Other long-term liabilities           2,962       2,654  
TOTAL LIABILITIES           53,242       47,935  
COMMITMENTS AND CONTINGENCIES      
EQUITY      
Preferred stock $0.005 par value; 100,000,000 shares authorized; no shares issued and outstanding           —       —  
Common stock $0.005 par value; 900,000,000 shares authorized; 443,266,000 and 443,237,000 shares issued and outstanding           2       2  
Additional paid-in capital           8,830       8,282  
Accumulated other comprehensive loss           (1,620 )     (1,770 )
Retained earnings           28,591       22,650  
TOTAL EQUITY           35,803       29,164  
TOTAL LIABILITIES AND EQUITY         $ 89,045     $ 77,099  
           

COSTCO WHOLESALE CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(amounts in millions) (unaudited)
   
Subject to Reclassification  
  52 Weeks Ended
  August 30,

2026 		  August 31,

2025
CASH FLOWS FROM OPERATING ACTIVITIES      
Net income         $ 9,226     $ 8,099  
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization           2,674       2,426  
Non-cash lease expense           318       303  
Stock-based compensation           924       860  
Other non-cash operating activities, net           355       (117 )
Changes in working capital           2,328       1,764  
Net cash provided by operating activities           15,825       13,335  
CASH FLOWS FROM INVESTING ACTIVITIES      
Additions to property and equipment           (6,435 )     (5,498 )
Purchases of short-term investments           (788 )     (1,028 )
Maturities of short-term investments           811       1,141  
Other investing activities, net           26       74  
Net cash used in investing activities           (6,386 )     (5,311 )
CASH FLOWS FROM FINANCING ACTIVITIES      
Repayments of short-term borrowings           (577 )     (862 )
Proceeds from short-term borrowings           553       816  
Repayments of long-term debt           (69 )     (103 )
Proceeds from issuance of long-term debt           496       —  
Tax withholdings on stock-based awards           (361 )     (393 )
Repurchases of common stock           (848 )     (903 )
Cash dividend payments           (2,458 )     (2,183 )
Financing lease payments and other financing activities, net           (91 )     (147 )
Net cash used in financing activities           (3,355 )     (3,775 )
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS           (38 )     6  
Net change in cash and cash equivalents           6,046       4,255  
CASH AND CASH EQUIVALENTS BEGINNING OF YEAR           14,161       9,906  
CASH AND CASH EQUIVALENTS END OF YEAR         $ 20,207     $ 14,161  



Posted on

ARMOUR Residential REIT, Inc. Announces Guidance for October 2026 Dividend Rate Per Common Share

VERO BEACH, Florida, Sept. 24, 2026 (GLOBE NEWSWIRE) — ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) (“ARMOUR” or the “Company”) today announced guidance on the October 2026 cash dividend for the Company’s Common Stock of $0.24 per Common share.

October 2026
Common Stock Dividend Information

Month   Dividend   Holder of Record Date   Payment Date
October 2026   $0.24   October 15, 2026   October 29, 2026

Certain Tax Matters

ARMOUR has elected to be taxed as a real estate investment trust (“REIT”) for U.S. Federal income tax purposes. In order to maintain this tax status, ARMOUR is required to timely distribute substantially all of its ordinary REIT taxable income. Dividends paid in excess of current tax earnings and profits for the year will generally not be taxable to common stockholders. Actual dividends are determined at the discretion of the Company’s board of directors, which may consider additional factors including the Company’s results of operations, cash flows, financial condition and capital requirements as well as current market conditions, expected opportunities and other relevant factors.

About ARMOUR Residential REIT, Inc.

ARMOUR invests primarily in fixed rate residential, adjustable rate and hybrid adjustable rate residential mortgage-backed securities issued or guaranteed by U.S. Government-sponsored enterprises or guaranteed by the Government National Mortgage Association. ARMOUR is externally managed and advised by ARMOUR Capital Management LP, an investment advisor registered with the Securities and Exchange Commission (“SEC”).

Safe Harbor

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. The Company disclaims any obligation to release publicly any updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

Additional Information and Where to Find It

Investors, security holders and other interested persons may find additional information regarding the Company at the SEC’s internet site at www.sec.gov, or the Company website at www.armourreit.com, or by directing requests to: ARMOUR Residential REIT, Inc., 3001 Ocean Drive, Suite 201, Vero Beach, Florida 32963, Attention: Investor Relations.

Investor Contact:        

Gordon Harper
Chief Financial Officer
ARMOUR Residential REIT, Inc.
(772) 617-4340



Posted on

NANOBIOTIX Provides First Half 2026 Operational and Financial Update

  • Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally recurrent non-small cell lung cancer (“NSCLC”) amenable to re-irradiation
  • Strengthened financial position through an oversubscribed ~€86 million global follow-on offering completed in May 2026, extending cash runway into 2029
  • Acceptable safety profile and promising initial efficacy responses observed in Johnson & Johnson-led Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3) in Stage 3 unresectable NSCLC
  • U.S. FDA clearance for protocol amendment to the Johnson & Johnson-led Phase 3 NANORAY-312 study evaluating JNJ-1900 (NBTXR3) in locally advanced platinum ineligible head and neck cancer
  • €110.9 million in cash and cash equivalents as of June 30, 2026

PARIS and CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today provided an update on operational progress and reported financial results for the first six months of 2026.

“Our progress in the first half of 2026 continues to support our belief that a physics-based approach to the design and development of nanotherapeutics has the potential to revolutionize treatment possibilities for millions of patients around the world,” said Laurent Levy, Chief Executive Officer and Chairman of the Executive Board at Nanobiotix. “The JNJ-1900 (NBTXR3) clinical development program continued to produce encouraging data across multiple indications, and adjustments to the Phase 3 NANORAY-312 protocol streamlined the study toward the final analysis. Longstanding shareholders and new investors alike expressed confidence in our vision through our recent capital raise. We enter the second half strategically, operationally, and financially equipped to continue supporting Nanoradioenhancer JNJ-1900 (NBTXR3) and advancing next wave nanotherapeutic platforms such as Nanoprimer.”

Operational Highlights

  • New data from Phase 1 NSCLC study sponsored by The University of Texas MD Anderson Cancer Center (“UT MD Anderson”) presented at 2026 WCLC Meeting:
    • At a median follow-up of 12 months, the one-year locoregional control rate was 79%. One-year local progression-free survival (“LPFS”) was 61%, and one-year overall survival (“OS”) was 70% in evaluable patients.
    • Investigators concluded that JNJ-1900 (NBTXR3) may permit clinically meaningful local control using a substantially lower re-irradiation dose.
    • All 24 patients completed treatment with JNJ-1900 (NBTXR3) plus re-irradiation with no dose-limiting toxicities
    • No Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3) or to the injection procedure were reported
    • The recommended Phase 2 dose was established at 33% of gross tumor volume
  • Included in the Euronext Tech Leaders segment and Euronext Tech Leaders Index, a Euronext flagship initiative dedicated to increasing the visibility and attractiveness of Europe’s leading and high-growth technology companies among international investors.
  • Closed a global follow-on offering with underwriters’ over-allotment option fully exercised, bringing total gross proceeds to approximately €86 million that will support continued develop of Nanobiotix’s broader therapeutic platforms
  • Part 1 data from Johnson & Johnson (“J&J”)-led Phase 2 JNJ-1900 (NBTXR3) Study in Unresectable Stage 3 NSCLC (CONVERGE) presented at ELCC 2026 and updated at ESTRO 2026
    • Initial investigator-reported efficacy responses observed in 7 patients following the full treatment regimen of JNJ-1900 (NBTXR3) given prior to concurrent chemoradiotherapy, and consolidation with durvalumab) showed:
      • Overall response rate (“ORR”) = 85.7% (6/7 patients) reported at ESTRO 2026
        • In the same cohort of 7 patients, ORR observed at earlier time point and reported at ELCC 2026 was 71.4% (5/7 patients)
      • Complete response rate (“CRR”) = 57.1% (4/7 patients) reported at ESTRO 2026
        • With the current standard of care, concurrent chemoradiation therapy (cCRT) + durvalumab, depth of response remains limited in Stage 3 unresectable NSCLC with very low rates of complete response (~15%)1
      • Deepening response over time suggests potential for long-term durability
      • The procedure demonstrated an acceptable safety profile without serious treatment-emergent adverse events (TEAEs)
    • Early results suggest that intratumoral/intranodal injection of JNJ-1900 (NBTXR3) is feasible and can be performed safely in patients with stage III unresectable NSCLC
  • Protocol amendment to J&J-led global Phase 3 JNJ-1900 (NBTXR3) study in Cisplatin-ineligible Head and Neck Cancer (NANORAY-312)
    • Eliminated previously planned interim analysis eliminated and modified the final analysis to include fewer events than originally planned to be conducted sooner
  • New preclinical data presented at 2026 AACR Meeting
    • Pre-treatment with Nanoprimer followed by administration of LNP-delivered recombinant DNA (“LNP-DNA”) designed for anti-tumor immunotherapy showed increased systemic bioavailability, reduced hepatic toxicity, and reduced cGAS-STING related inflammation compared to LNP-DNA administered without the Nanoprimer

Half Year 2026 Financial Results


Revenue and Other Income

: Revenue and other income amounted to €5.6 million for the six months ended June 30, 2026, as compared to €26.6 million for the same period in 2025. This variance is mainly due to a significant one-off non-cash revenue positive impact amounting to €21.2 million recorded over the first half of 2025 in accordance with IFRS15 revenue recognition accounting principles, further to the transfer of NANORAY-312 study sponsorship to Johnson & Johnson. In addition, Revenue and Other Income for the six months ended June 30, 2026 also included €3.1 million of clinical product supply sales to Johnson & Johnson (as compared to €3.4 million for the same period in 2025) and research tax credit income amounting to €1.9 million (as compared to €1.6 million for the same period in 2025).


Research and Development (“R&D”) Expenses:
 R&D expenses consist primarily of preclinical, clinical and manufacturing expenses including employee-related payroll costs and shared-based payment charges related to the development of JNJ-1900 (NBTXR3) and of new platforms. These R&D expenses for the six months ending June 30 2026, were €12.7 million as compared to €14.5 million for the same period in 2025. The €1.8 million favorable variance was primarily driven by lower clinical development and JNJ-1900 (NBTXR3) production activities in NANORAY-312 study further to the transfer of sponsorship to Johnson & Johnson, and by less patient recruitment on the studies Study 1100 and lower UT MD Anderson studies expense during first half of 2026 as compared to the same period in 2025.


Selling, General and Administrative (“SG&A”) Expenses:
 SG&A expenses consist primarily of administrative employee-related payroll costs, share-based payment charges, insurance, IP, legal, audit and other professional fees. Total SG&A expenses for the six months ending June 30, 2026, were €10.8 million, as compared to €11.3 million for the same period in 2025. The €0.5 million favorable variance is mainly due to the impact of social charges related to stock-option plan and severance expenses occurred over the first half of 2025.


Net loss:
 Net loss attributable to common shareholders for the six months ending June 30, 2026, was €34.3 million, or a €0.70 basic loss per share. This compares to a net loss attributable to common shareholders of €5.4 million, or €0.11 basic loss per share, for the same period in 2025.


Cash and Cash Equivalents:
 Cash and Cash Equivalents as of June 30, 2026 were €110.9 million, compared to €52.8 million as of December 31, 2025.


Financial Guidance
: Based on the current operating plan and financial projections, the Company anticipates that the cash and cash equivalents of €110.9 million as of June 30, 2026 will fund its operations into 2029.

Availability of the Half Year 2026 Financial Reports

The 2026 half-year financial report has been filed with the French financial market authority (Autorité des marchés financiers) and with the U.S. Securities and Exchange Commission on September 24, 2026. It is available to the public on the Company’s website, www.nanobiotix.com.

About JNJ-1900 (NBTXR3)

JNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles administered via one-time intratumoral injection and activated by radiotherapy. The product candidate’s mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when in the presence of radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Proof-of-concept was demonstrated in a randomized Phase 2/3 soft tissue sarcoma study sponsored by Nanobiotix in 2018.

JNJ-1900 (NBTXR3) is being evaluated across multiple solid tumor indications as a single agent or combination therapy. Given the Company’s focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating JNJ-1900 (NBTXR3) across tumor types and therapeutic combinations.

In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy.

In 2023, Nanobiotix announced a license agreement for the global development and commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a Johnson & Johnson company. Studies being led by Johnson & Johnson include NANORAY-312 (NCT04892173), a global, randomized Phase 3 study in platinum-based chemotherapy-ineligible, locally advanced head and neck squamous cell cancers; LUMIRAY (NCT07219212), a global, phase 1b, open-label study in locally advanced head and neck squamous cell cancers; and CONVERGE (NCT06667908), a phase 2, randomized, open-label, active-controlled study in locally advanced and unresectable Stage III non-small cell lung cancer (NSCLC).

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Disclaimer

This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company’ management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on March 31, 2026 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2025 universal registration document filed with the AMF on March 31, 2026 under “chapter 1.5 Risk Factors”, and subsequent filings Nanobiotix makes with the SEC and AMF from time to time, including the Half-Year Report at June 30, 2026, which are available on the SEC’s website at www.sec.gov and on the AMF’s website at www.amf.org, The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.

Nanobiotix  
Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835
[email protected]		 Investor Relations Department

Joanne Choi

VP, Investor Relations (US)

+1 (713) 609-3150
[email protected]

Ricky Bhajun
Director, Investor Relations (EU)
+33 (0) 79 97 29 99
[email protected]

  
Media Relations  

France – HARDY
Caroline Hardy
+33 6 70 33 49 50
[email protected]
Global – uncapped
Becky Lauer
+1 (646) 286-0057
[email protected]		  

1Antonia SJ, et al. N Engl J Med. 2017.

Attachment



Posted on

Big Sky Industrial Inc. to Participate in the Noble Capital Markets’ Emerging Growth Virtual Equity Conference

HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) — Big Sky Industrial Inc. (NASDAQ: BSIN) (“Big Sky Industrial” or the “Company”), an integrated industrial gas, energy, and carbon management company, today announced that its Chief Executive Officer, Ryan Smith, will participate in the Noble Capital Markets’ Emerging Growth Virtual Equity Conference on October 1.

During the event, Mr. Smith will present and host one-on-one meetings with investors. The presentation is currently scheduled to take place at 8:30 a.m. ET on October 1. The presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience.

Investors can view the live presentation at https://channelchek.cc/4yDOCxz or register for the event at no cost here.

To request a meeting with the Big Sky Industrial team, please reach out to Giorgia Pigato, from Noble Capital Markets, at [email protected] or the Company’s investor relations team at [email protected].

A video webcast of the presentation will be available following the event on the Company’s website at www.bigskyindustrialinc.com. The webcast will be archived on the company’s website for 90 days following the event.

About Big Sky Industrial Inc.

Big Sky Industrial Inc. (NASDAQ: BSIN) is a Houston-based industrial gas, carbon management, and energy company with operations focused on the Big Sky Carbon Hub and Cut Bank oil field in Montana’s Kevin Dome region. The Company’s asset base supports three distinct business lines: helium production, carbon management, and low-decline oil production. Big Sky Industrial is focused on developing an integrated platform that leverages helium as a federally designated critical mineral, carbon management opportunities supported by Section 45Q federal tax credits, and conventional oil production from its owned and operated assets. The Company’s operations are designed to generate revenue from multiple independent sources across helium, carbon management, and oil. For more information, please visit www.bigskyindustrialinc.com.

INVESTOR RELATIONS CONTACT

Mason McGuire
[email protected]
(303) 993-3200
www.bigskyindustrialinc.com



Posted on

FG Nexus Inc. Announces Name Change to FG Communities Holdings Inc.

Ticker symbols to change from FGNX and FGNXP to FGC and FGCPP on Nasdaq

Charlotte, NC, Sept. 24, 2026 (GLOBE NEWSWIRE) — FG Nexus (Nasdaq: FGNX, FGNXP) (the “Company”) announced that it has filed a Certificate of Amendment to its amended and restated articles of incorporation with the Nevada Secretary of State. Pursuant to the Certificate of Amendment, the Company will change its name to FG Communities Holdings Inc. In conjunction with the name change, the Company’s ticker symbols on The Nasdaq Stock Market will change as follows to: FGC for its Common Stock replacing the previous symbol “FGNX” and FGCPP for its Series A Preferred Shares, replacing the previous symbol “FGNXP,” effective at market open on Monday, September 28, 2026.

Kyle Cerminara, Chairman and CEO, commented, “We have made tremendous progress evolving our business model, and the new name better reflects our transformation into a leading owner and operator of land-lease affordable housing communities. We look forward to driving sustained long-term value for our shareholders.”


About FG Nexus Inc.

FG Nexus (Nasdaq: FGNX, FGNXP) is a merchant bank and real estate focused operating company.

The FGNX® logo is a registered trademark.


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are entitled to the protection of the safe-harbor provisions of those laws.

Forward-looking statements include statements concerning the closing and anticipated benefits of the Company’s proposed investment in FG Communities; the Company’s strategy to make direct investments in affordable housing communities; the acquisition, ownership, operation and financing of manufactured housing communities; the use of cash, debt financing and proceeds from common-stock issuances to fund acquisitions; the proposed corporate name and ticker-symbol changes; future share repurchases; the Company’s acquisition pipeline and growth strategy; and the anticipated size and long-term characteristics of the manufactured housing market.

These statements are based on management’s current expectations, assumptions, estimates and projections and involve risks and uncertainties, many of which are beyond the Company’s control. Actual results could differ materially from those expressed or implied by these statements.

Relevant risks include, among others, the Company’s ability to complete the proposed investment on anticipated terms; obtain required corporate, regulatory and Nasdaq approvals; successfully identify, finance, complete and integrate property acquisitions; obtain debt or equity financing on acceptable terms; manage leverage and potential dilution from equity issuances; realize anticipated operating and financial benefits; maintain adequate liquidity; and appropriately manage potential conflicts of interest arising from related-party transactions.

Additional risks are described in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statement except as required by law.

Contacts

Media Contact

[email protected]

Investor Contact

[email protected]



Posted on

Spectral AI Announces Upcoming Presentation at ACS Clinical Congress 2026 Highlighting the Use of Artificial Intelligence and Multi-Spectral Imaging in the Assessment of Burn Wounds

DALLAS, Sept. 24, 2026 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced a scheduled presentation at the upcoming ACS Clinical Congress 2026, being held September 26-29, 2026 in Washington, DC.

Entitled “Artificial Intelligence Training & Validation of Multi-Spectral Imaging Device for Evaluation of Burn Wounds,” the presentation will be led by James H. Holmes IV, MD, FACS, FABA, Director of the Burn Center at Atrium Health Wake Forest Baptist Medical Center and Professor of Surgery and Regenerative Medicine at Wake Forest University. The study reflects the contributions of a multidisciplinary group of clinicians and researchers from leading burn centers and academic institutions across the country, including Dr. J. Michael DiMaio, Spectral AI’s Chairman of the Board.

“We are pleased that the important work of Dr. Holmes and his colleagues will be featured at ACS Clinical Congress, one of the leading forums for surgical innovation and clinical education,” said Vincent Capone, Chief Executive Officer.   “The opportunity to introduce DeepView to the broader surgical community is particularly important as we advance commercialization of our FDA-cleared DeepView System for Burn Indication. While DeepView has been developed in close collaboration with leading burn surgeons and burn centers, burn patients are initially evaluated and treated across a much broader range of surgical and acute-care settings. Expanding awareness and understanding of DeepView among surgeons beyond the burn specialty is an important step in bringing this technology to the broader continuum of burn care.”

ASC Clinical Congress 2026 brings together surgeons, clinical leaders, researchers and educators from across surgical specialties to address important and emerging topics in clinical practice, surgical education, research and technology. Spectral AI believes the presentation provides an important opportunity to increase awareness of DeepView beyond the specialized burn community and introduce the technology to a broader group of surgeons who may encounter and manage burn patients throughout the continuum of care.


About the DeepView


®


System

Spectral AI’s DeepView System is a non-invasive, predictive medical device that combines multispectral imaging with a proprietary AI algorithm to assess the healing potential of areas within burn wounds. It was granted De Novo Classification by the U.S. Food and Drug Administration (“FDA”) in May 2026 and received its initial UKCA (UK Conformity Assessed) authorization in the United Kingdom in February 2024. The DeepView System provides physicians with an immediate, data-driven assessment of whether areas within burn wounds are unlikely to heal within 21 days and may require significant medical intervention, enabling earlier and more informed treatment decisions. The image acquisition takes 0.2 seconds, and all image processing and AI model classification takes approximately 20 to 25 seconds. The DeepView System is trained and tested against a proprietary and clinically validated database of over 340 billion pixels of burn wound image data.


About Spectral AI

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. The DeepView System is a predictive diagnostic device that offers physicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal to exceed the current standard of care, the DeepView System provides fast and accurate treatment insights to improve patient outcomes and reduce healthcare costs. Spectral AI has been named to TIME’s list of World’s Top HealthTech companies 2025. For more information about the DeepView System, visit www.spectral-ai.com.

The Company’s contract with the Biomedical Advanced Research and Development Authority (“BARDA”) is held and performed through its wholly owned subsidiary, Spectral MD. References to the contract, associated awards, related revenue, business opportunities, obligations, and other relevant factors should be understood to refer to Spectral MD as the contracting party unless otherwise indicated.


Forward-Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements. 

Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the US Securities and Exchange Commission, including the Company’s Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. 

Investors:  
The Equity Group  
Devin Sullivan Conor Rodriguez
Managing Director Associate
[email protected] [email protected]



Posted on

Vivmark Residential Declares Third Quarter Dividends

Vivmark Residential Declares Third Quarter Dividends

ARLINGTON, Va. & CHICAGO–(BUSINESS WIRE)–Vivmark Residential (NYSE: VMRK) today announced that its Board of Trustees declared quarterly dividends on the Company’s common and preferred shares. A regular common share dividend for the third quarter of $0.7025 per share will be paid on October 16, 2026, to shareholders of record on October 5, 2026.

A quarterly dividend of $1.03625 per share will be paid on September 30, 2026, to shareholders of record on September 18, 2026, of the Company’s Series K Preferred Shares.

Vivmark Residential was created through a merger of equals between AvalonBay Communities, Inc. (AVB) and Equity Residential (EQR), which closed on August 17, 2026.

About Vivmark Residential

Vivmark Residential (NYSE: VMRK), an S&P 500 company, sets the mark for what home can be, and our vision is to be the most trusted and best-performing rental housing company in America, one that only gets better as it grows. Our people, scale and capabilities create a self-reinforcing performance cycle that delivers structurally higher growth. With more than 184,000 apartment homes across premier U.S. markets and over $4.4 billion in active development, Vivmark is redefining what rental housing can be. For more details, please visit www.vivmarkresidential.com.

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. These statements, among other things, are based on current expectations, estimates and projections about the industry and markets in which Vivmark Residential (“Vivmark” or, together with its subsidiaries, “we,” “us” or “our”) (f/k/a Equity Residential) operates, as well as beliefs and assumptions of Vivmark. Words such as “anticipate,” “become,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “target,” “seek,” “shall,” “should,” “will,” or “would,” including variations of such words and similar expressions, are intended to identify forward-looking statements. All statements that address operating performance, events or developments that Vivmark expects or anticipates will occur in the future are forward-looking statements, including statements relating to the anticipated synergies, cost savings and other benefits of the Merger (as defined below), integration plans, projected dividends, development net operating income, accretion and value creation, multifamily market conditions, development, redevelopment, acquisition or disposition activity, general conditions in the geographic areas where Vivmark operates and Vivmark’s debt, capital structure and financial position. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other factors that are difficult to predict and may cause the actual results to differ materially from future results expressed or implied by such forward-looking statements.

Important factors, risks and uncertainties that could cause actual results to differ materially from such plans, estimates or expectations include but are not limited to: the inability to realize the anticipated benefits of the merger (the “Merger”) between AvalonBay Communities, Inc. (“AvalonBay”) and Equity Residential (which Merger formed Vivmark), including as a result of an integration of the two businesses that is unsuccessful or that is more difficult, time-consuming or costly than expected; unknown or inestimable liabilities that arise as a result of the Merger; potential litigation relating to the Merger that could be instituted against Vivmark or its trustees, managers or officers, including resulting expense and the effects of any outcomes related thereto; the risk that disruptions related to the Merger or post-Merger integration and other efforts, and resulting diversion of the attention of Vivmark management from ongoing business operations, will harm Vivmark’s businesses; the possibility that the post-Merger integration of the two businesses may be more expensive to complete than anticipated; potential business uncertainty, including changes to existing business relationships with tenants, employees, joint venture partners and third parties, following the Merger that could affect Vivmark’s financial performance; increased costs of labor and construction material, including as a result of several of the other factors discussed in this section and elsewhere; maintenance of real estate investment trust status, tax structuring and changes in income tax laws and rates; potential failure to secure development opportunities due to an inability to reach agreements with third parties to obtain land at attractive prices or to obtain desired zoning and other local approvals; abandonment or deferment of development opportunities for a number of reasons, including changes in local market conditions, increases in costs of development, increases in the cost of capital or lack of capital availability, resulting in losses; increases in Vivmark’s borrowing costs as a result of changes in interest rates, rising inflation and other factors; construction costs of a community may exceed original estimates; inability to complete construction and lease-up of communities under development or redevelopment on schedule, resulting in increased interest costs and construction costs and a decrease in expected rental revenues; occupancy rates and market rents being adversely affected by competition and local economic and market conditions which are beyond our control; geopolitical conditions and instability, and international trade disputes, including any related tariffs, which may lead to rising inflation, adverse impacts to supply chains, and disruption of, or lack of access to, the capital markets, as well as potential volatility in Vivmark’s share price; our cash flows from operations and access to cost-effective capital potentially being insufficient for the development of our pipeline, which could limit our pursuit of opportunities; an outbreak of disease or other public health event may affect the multifamily industry and general economy; our cash flows potentially being insufficient to meet required payments of principal and interest, and inability to refinance existing indebtedness or the terms of such refinancing may not be as favorable as the terms of existing indebtedness; lack of success in our management of joint ventures and the REIT vehicles that are used with certain joint ventures; a casualty loss, natural disaster or severe weather event, including those caused by climate change; an increase in the level of new multifamily communities construction and development, which may cause heightened competition for tenants and increased pressure on our rental rates; new or existing laws and regulations that adversely impact the markets in which we operate or our business, including those relating to rent control or rent stabilization, or that otherwise limit our ability to increase rents, charge non-rent fees or evict tenants, may impact our revenue or increase our costs; risks related to our reliance on information technology systems, data and artificial intelligence or other automated tools, including cybersecurity incidents and other privacy or data security events, evolving regulation of the collection and use of resident data and of automated or algorithmic tools, and the failure of such systems or tools to perform as intended; our expectations, estimates and assumptions as of the date of this communication regarding legal proceedings changing, including as a result of the Merger; the possibility that we may choose to pay dividends in our shares instead of cash, which may result in shareholders having to pay taxes with respect to such dividends in excess of the cash received, if any; and investments made under our structured investment program may not be repaid as expected or the development may not be completed on schedule, which could require us to engage in litigation, foreclosure actions, and/or first party project completion to recover our investment, which may not be recovered in full or at all in such event; a downgrade in our credit ratings that could increase our borrowing costs and adversely affect our liquidity and ability to access the capital markets, including the commercial paper market; and those risks and uncertainties set forth in Equity Residential’s and AvalonBay’s respective Annual Reports on Form 10-K for the year ended December 31, 2025 under the headings “Forward-Looking Statements” and “Risk Factors,” as such risk factors may be amended, supplemented or superseded from time to time by Vivmark’s subsequent filings with the Securities and Exchange Commission (the “SEC”) and those risks described under “Risk Factors” in the definitive joint proxy statement/prospectus of Equity Residential and AvalonBay, dated July 13, 2026, including the risks related to the combined company described therein, in each case which are available via the SEC’s website at www.sec.gov.

These factors should not be construed as exhaustive and should be read in conjunction with the other forward-looking statements. Forward-looking statements relate only to events as of the date on which the statements are made. Vivmark does not undertake any obligation to publicly update or revise any forward-looking statement except as required by law, whether as a result of new information, future developments or otherwise. If one or more of these or other risks or uncertainties materialize, or if Vivmark’s underlying assumptions prove to be incorrect, Vivmark’s actual results may vary materially from what Vivmark may have expressed or implied by these forward-looking statements. Vivmark cautions not to place undue reliance on any of Vivmark’s forward-looking statements. Furthermore, new risks and uncertainties arise from time to time, and it is impossible for us to predict those events or how they may affect Vivmark. Certain statements in this communication are derived from the standalone 2026 guidance previously reported by AvalonBay and Equity Residential; such guidance speaks only as of the date it was originally issued.

Investor Contacts
Marty McKenna
[email protected]

Matt Grover
[email protected]

Media Contact
Tara Vales
[email protected]

KEYWORDS: United States North America Illinois Virginia

INDUSTRY KEYWORDS: Construction & Property Residential Building & Real Estate

MEDIA:

Posted on

The First Bancorp Declares Third Quarter Dividend

The First Bancorp Declares Third Quarter Dividend

DAMARISCOTTA, Maine–(BUSINESS WIRE)–
The First Bancorp (NASDAQ: FNLC), the parent company of First National Bank, today declared a quarterly cash dividend of 38 cents per share. This third quarter dividend is payable October 16, 2026 to shareholders of record as of October 6, 2026.

“The Board of Directors voted today to authorize a dividend of 38 cents per share for the third quarter of 2026,” remarked President & Chief Executive Officer, Tony C. McKim. “We’ve enjoyed a strong start to 2026 and are pleased to have shareholders participate in the Company’s success at a meaningful level. Based on a closing price of $33.98 per share on September 23, 2026, the annualized dividend of $1.52 per share represents an attractive yield of 4.47%.”

The First Bancorp, headquartered in Damariscotta, Maine, is the holding company for First National Bank. Founded in 1864, the Bank serves Mid-Coast and Down East Maine with eighteen offices in Lincoln, Knox, Hancock, Penobscot, Waldo and Washington Counties. The Bank provides a full range of consumer and commercial banking products and services. First National Wealth Management, a division of First National Bank, provides investment management and trust services from five offices in Lincoln, Knox, Penobscot and Hancock Counties.

Forward-looking and cautionary statements: except for the historical information and discussions contained herein, statements contained in this release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results and events to differ materially, as discussed in the Company’s filings with the Securities and Exchange Commission.

Category: Dividends

Source: The First Bancorp

The First Bancorp

Richard M. Elder, EVP, Chief Financial Officer

207-563-3195

[email protected]

KEYWORDS: United States North America Maine

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Posted on

Ameriprise Financial Announces Schedule for Third Quarter 2026 Investor Conference Call

Ameriprise Financial Announces Schedule for Third Quarter 2026 Investor Conference Call

MINNEAPOLIS–(BUSINESS WIRE)–
Ameriprise Financial, Inc. (NYSE: AMP) plans to issue a press release via Business Wire at approximately 8:15 a.m. ET on Thursday, October 29, 2026 that will include a link to the company’s third quarter 2026 results on its Investor Relations website (ir.ameriprise.com). The earnings results will also be furnished to the Securities and Exchange Commission on a Form 8-K. The company will host an investor conference call to review the results at approximately 9:00 a.m. ET the same day.

Earnings materials, live audio of the conference call and an audio replay will be available on the firm’s Investor Relations website.

At Ameriprise Financial, we have been helping people feel confident about their financial future for more than 130 years. With extensive investment advice, global asset management capabilities and insurance solutions, and a nationwide network of more than 10,000 financial advisors, we have the strength and expertise to serve the full range of individual and institutional investors’ financial needs.

© 2026 Ameriprise Financial, Inc. All rights reserved.

Paul Johnson

Ameriprise Financial

612.671.0625

[email protected]

KEYWORDS: United States North America Minnesota

INDUSTRY KEYWORDS: Professional Services Insurance Finance Asset Management Consulting Personal Finance

MEDIA:

Logo
Logo
Posted on

Acuity Inc. Declares Quarterly Dividend

Atlanta, Sept. 24, 2026 (GLOBE NEWSWIRE) — Acuity Inc. (NYSE: AYI) will pay a quarterly dividend of 20 cents per share. The dividend is payable on November 2, 2026, to shareholders of record on October 16, 2026.

About Acuity 

Acuity Inc. (NYSE: AYI) is a market-leading industrial technology company. We use technology to solve problems in spaces, light and more things to come. Through our two business segments, Acuity Brands Lighting (ABL) and Acuity Intelligent Spaces (AIS), we design, manufacture, and bring to market products and services that make a valuable difference in people’s lives.

We achieve growth through the development of innovative new products and services, including lighting, lighting controls, building management solutions, and an audio, video and control platform. We focus on customer outcomes and drive growth and productivity to increase market share and deliver superior returns. We look to aggressively deploy capital to grow the business and to enter attractive new verticals.

Acuity Inc. is based in Atlanta, Georgia with operations across North America, Europe and Asia. The Company is powered by approximately 13,000 dedicated and talented associates. Visit us at www.acuityinc.com.

Investor Contact: 

Charlotte McLaughlin 
Vice President, Investor Relations 
(404) 853-1456 
[email protected] 

Media Contact:  

April Appling
Senior Vice President, Corporate Marketing and Communications
[email protected]